Life Sciences

  • May 05, 2026

    Apple Urges Full Fed. Circ. To Undo Original Watch Import Ban

    A Federal Circuit panel erred when finding the U.S. International Trade Commission properly banned imports of Apple Watches with blood oxygen-monitoring features, the tech giant behind the devices said in a plea for rehearing by the full court.

  • May 05, 2026

    $100M AI Investment Suit Must Be Arbitrated, Financier Says

    A California financier Tuesday denied allegations in a $100 million fraud lawsuit over a "sham" loan transaction aimed at funding an investment into an artificial intelligence company, adding that the dispute belongs in arbitration in the Bahamas.

  • May 05, 2026

    Mylan Strikes $4.5M Deal With Maryland Over EpiPen Pricing

    Mylan Pharmaceuticals will pay $4.5 million to resolve allegations by the state of Maryland that Mylan acted anticompetitively when it ratcheted up costs of its portable auto-injectable EpiPen device that's used during life-threatening allergic reaction episodes, according to a recent announcement.

  • May 05, 2026

    4th Circ. Backs Raytheon In Ex-Workers' Vaccine Bias Case

    The Fourth Circuit upheld RTX Corp.'s defeat of a lawsuit claiming it forced out employees who received religious exemptions to its COVID-19 vaccine policy, ruling Tuesday that the ex-workers behind the suit filed their claims too late.

  • May 05, 2026

    Amylyx Investors To Get $6.5M In ALS Drug Settlement

    Amylyx Pharmaceuticals and a class of shareholders are seeking judicial approval for a $6.5 million settlement to resolve allegations that the drugmaker overstated the commercial potential of a treatment for amyotrophic lateral sclerosis, or ALS, that was ultimately shelved.

  • May 05, 2026

    CooperSurgical Strikes Deal To End Embryo Loss Class Suit

    Connecticut-based fertility products manufacturer CooperSurgical Inc. has reached a settlement with a proposed class of in vitro fertilization patients and their partners, who claimed the company's defective product caused the loss of their embryos.

  • May 05, 2026

    Sandoz, Novartis Must Face Generics Claims From GM, Others

    A Pennsylvania federal judge largely refused to let dozens of generic-drug makers duck stand-alone price-fixing and market allocation antitrust claims from major employers like General Motors, American Airlines and Lowe's, nixing allegations against a small handful while importantly preserving them against Novartis and its former Sandoz subsidiary.

  • May 05, 2026

    Deutsche, Pathward Want Fintech Blacklist Suit Tossed

    Deutsche Bank AG and Pathward NA urged a New York federal court to dismiss a suit accusing them of improperly blacklisting a barter-based payment platform that the banks found was "transaction laundering" for companies selling gray-market pharmaceuticals, arguing that the suit's jurisdiction assertions are fatal to the claims.

  • May 05, 2026

    Travelers Unit Says No Coverage In Cannabis Explosion Suits

    A Travelers Property Casualty Corp. unit is suing two of its insureds in California federal court, seeking a declaration that its insurance policies don't cover defense and indemnity of suits over a deadly explosion allegedly caused by an illegal cannabis operation.

  • May 04, 2026

    'They Knew It': J&J Accused Of Hiding Talc Risk At LA Trial

    Johnson & Johnson knew for decades that its baby powder contained asbestos, even as it advertised the product as safe and "pure," attorneys for the families of three women who died of ovarian cancer told a California jury Monday during opening statements in a bellwether trial.

  • May 04, 2026

    Biotech Overhyping Obesity Drug Hurt Investors, Suit Says

    Current and former executives of drugmaker Skye Bioscience Inc. breached their fiduciary duties by overstating an obesity drug's clinical prospects and precipitating a trading price decline when the company revealed disappointing study results, an investor has alleged.

  • May 04, 2026

    Judge Shuts Down Invalidity Theory In Abiomed IP Case

    A Massachusetts federal judge has foreclosed one of Abiomed's invalidity defenses in a case brought by rival medical technology firm Maquet over alleged infringement of a patent covering blood pump technology.

  • May 04, 2026

    Supplement Co. Says False Labeling Plaintiff Never Saw Ads

    The maker of Thesis Nootropics supplements is asking a New York federal court to throw out claims that it falsely advertises its products as ADHD medications, saying the plaintiff hasn't sufficiently alleged she ever saw the advertisements or even used the products.

  • May 04, 2026

    Supreme Court Halts Abortion Drug Telehealth Ruling

    The U.S. Supreme Court on Monday temporarily reinstated telehealth access for the abortion medication mifepristone, pausing a lower-court order that had blocked by-mail and remote prescriptions.

  • May 04, 2026

    Justices Won't Hear Anti-Vaxxer Medical Board Suit

    The U.S. Supreme Court on Monday said it will not review a petition brought by Health and Human Services Secretary Robert F. Kennedy Jr. on behalf of doctors who challenged a Washington state medical board's investigation into an alleged COVID-19 misinformation campaign.

  • May 01, 2026

    Pharma Aims Torpedo At FCA After Bombshell 9th Circ. Ruling

    A burgeoning campaign against the False Claims Act's whistleblower mechanism is suddenly center stage at the Ninth Circuit, where pharmaceutical companies say a momentous new ruling "illustrates perfectly" the constitutional concerns of U.S. Supreme Court justices regarding FCA enforcement.

  • May 01, 2026

    Judge, Atty Get In Shouting Match At Fatal Overdose Trial

    Tensions boiled over in a Philadelphia courtroom Friday at the end of an emotionally fraught trial over a man's fatal opioid overdose, with a judge and lawyer shouting at each other about how to figure out an inconclusive verdict spurred by a seemingly confused juror.

  • May 01, 2026

    Twist Bioscience Investors Seek $17M Stock Fraud Deal OK

    Twist Bioscience Corp. and two executives asked a California federal court to give preliminary approval to a $17 million deal they inked with investors to resolve class allegations the company misrepresented that its technology could produce synthetic DNA at higher quality and lower cost than competitors.

  • May 01, 2026

    Amazon Accused Of Selling Kids Sunscreen With Lead

    Consumers on Thursday hit Amazon with a proposed class action in Washington federal court alleging that children's sunscreens it sells are contaminated with heavy metals such as lead and that its artificial intelligence shopping assistant Rufus doesn't disclose details about the product ingredients.

  • May 01, 2026

    Fla. Jury Hears Menthol Smoker Succumbed To Addiction

    A Florida jury heard in opening arguments Friday that a woman who died of lung cancer after smoking R.J. Reynolds cigarettes was a victim of the severely addictive nature of nicotine, something her lawyers said even the U.S. surgeon general didn't acknowledge until 1988.

  • May 01, 2026

    Texas High Court Revives Delta-8 THC Restrictions

    The Lone Star State's health commissioner has the power to ban manufactured delta-8 THC goods, the Texas Supreme Court ruled Friday, lifting a lower court's order that had allowed hemp companies to keep selling these products while they sued the state.

  • May 01, 2026

    Biotech IPOs Surge Ahead As 2 Listings Raise $557M

    A pair of biotechnology firms began trading on Friday after raising a combined $557 million through upsized initial public offerings that both priced at the top of their proposed $16 to $18 ranges, marking the latest drug developers to join the IPO market in recent weeks.

  • May 01, 2026

    5th Circ. Pauses Mail-Order Access To Abortion Pills

    The Fifth Circuit on Friday reinstated an in-person dispensing requirement for the abortion medication mifepristone, blocking mail-order access while a challenge to a Biden administration regulation brought by Louisiana officials moves forward.

  • May 01, 2026

    Pharma Co. Investor Sues Over Misleading Aurinia Deal

    A Kezar Life Sciences investor has filed suit asking an Illinois federal judge to halt the company's planned acquisition by a Canadian biopharmaceutical company's U.S. unit unless Kezar fixes the "incomplete and misleading" regulatory filings it submitted regarding the transaction.

  • May 01, 2026

    Biotech Firm Wants Do-Over After Consultant's $58M Verdict

    A Georgia-based medical technology firm that was hit with a $58 million verdict last month over claims that it conspired to have a former consultant arrested has asked a Fulton County judge for a new trial, arguing the court allowed a jury charge that was "erroneous, irrelevant, [and] not tailored to the evidence."

Expert Analysis

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Software Patents May Face New Eligibility Scrutiny

    Author Photo

    November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

  • Riding The Changing Winds For AI Innovations At The USPTO

    Author Photo

    As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.

  • Series

    The Law Firm Merger Diaries: Integrating Practice Groups

    Author Photo

    Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.

  • Opinion

    Supreme Court Term Limits Would Carry Hidden Risk

    Author Photo

    While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Next Steps For Orgs. Amid Updated OpenAI Usage Policies

    Author Photo

    OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.

  • Series

    Knitting Makes Me A Better Lawyer

    Author Photo

    Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.

  • How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation

    Author Photo

    On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.

  • Series

    The Biz Court Digest: Welcome To Miami

    Author Photo

    After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.